Alamar Biosciences, Inc. Common Stock (ALMR) is a publicly traded the market company. As of July 10, 2026, ALMR trades at $26.17 with a market cap of $1.75B and a P/E ratio of 0.00. ALMR moved -1.17% today. Year to date, ALMR is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $18.85 to $28.68. Analyst consensus is strong buy with an average price target of $30.00. Rallies surfaces ALMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alamar Biosciences’ NULISA Featured in 140+ Presentations at AAIC, Showcases eMTBR-Tau and BD-pTau217 Assays: Alamar Biosciences’ NULISA platform is featured in more than 140 poster and session presentations at the Alzheimer’s Association International Conference in London July 12-15, quadrupling prior AAIC presence. A July 14 workshop will present data on eMTBR-Tau and BD-pTau217 assays measured alongside over 220 proteins, enhancing disease staging accuracy.
| Metric | Value |
|---|---|
| Price | $26.17 |
| Market Cap | $1.75B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.68 |
| 52-Week Low | $18.85 |
| Volume | 8.22K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover ALMR: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.00.